MedTrace Logo

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

NCT07122882 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-03-17

No results posted yet for this study

Summary

Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resistance against TKI in clinical practice. Therefore, understanding the molecular mechanisms underlying the acquired resistance is a critical issue in lung cancer. Based on the literature, acquired resistance mechanism against EGFR TKI includes EGFR secondary mutation (T790M, C797X, L792X, G796X, L718Q, and exon 20 insertions), MET amplification, HER2 amplification, acquired gene fusions, and other complex alterations.

From the perspective of mutagenesis, the acquired resistance against TKI may be associated with APOBEC mutational processes, kataegis, chromothripsis, extrachromosomal DNA (ecDNA), and the interaction among them. However, still 30% to 50% of oncogene-driven NSCLCs had no identified mechanism attributed to the acquired resistance. Previous studies mostly used targeted-gene sequencing, which may overlook some structural variation and the transcriptomic dynamics. This study aims to investigate the genomic alterations, mutational processes, and the transcriptomic landscape underlying the acquired resistance using integrated genomics.

Conditions

  • Oncogene-addicted Non Small Cell Lung Cancer
  • EGFR Mutation
  • ALK Fusion-positive Solid or CNS Tumors
  • ROS1 Fusion Positive
  • RET Fusion Positive
  • ERBB2 Mutation-Related Tumors
  • NTRK1 Fusion Positive
  • NTRK2 Fusion Positive
  • NTRK3 Fusion Positive
  • NRG1 Fusion
  • BRAF V600 Mutation
  • KRAS G12C Mutation
  • MET Exon 14 Skipping Mutation

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-05-11
Completion
2028-05-11

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122882 on ClinicalTrials.gov